Free Trial

Organigram Q2 2023 Earnings Report

Organigram logo
C$1.58 +0.03 (+1.94%)
As of 12:50 PM Eastern

Organigram EPS Results

Actual EPS
-C$0.02
Consensus EPS
-C$0.02
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Organigram Revenue Results

Actual Revenue
$39.49 million
Expected Revenue
$43.73 million
Beat/Miss
Missed by -$4.24 million
YoY Revenue Growth
N/A

Organigram Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Organigram Earnings Headlines

Trump doesn’t give a damn
Porter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met with one of Trump’s longest-serving advisors. We helped put together a plan to help investors capitalize on Trump’s election. And we found out these 10 stocks are the most likely to boom…
Haywood Reaffirms Their Buy Rating on OrganiGram Holdings (OGI)
See More Organigram Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Organigram? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organigram and other key companies, straight to your email.

About Organigram

Organigram (TSE:OGI) Inc. is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.

View Organigram Profile

More Earnings Resources from MarketBeat